Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8866 USD | +5.55% | +2.35% | +48.14% |
05-14 | Viracta Therapeutics Appoints Michael Faerm CFO | MT |
05-14 | Viracta Therapeutics, Inc. Appoints Michael Faerm as Chief Financial Officer | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+48.14% | 32.99M | |
+33.07% | 49.46B | |
+2.08% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+12.08% | 26.61B | |
-22.56% | 18.64B | |
+8.43% | 13.16B | |
+30.32% | 12.55B | |
+24.00% | 12.1B |
- Stock Market
- Equities
- VIRX Stock
- News Viracta Therapeutics, Inc.
- Viracta Says Epstein-Barr Therapy Had 40% Overall Response Rate in Trial; Shares Fall